Galapagos Expands its Collaboration with Serono
News Oct 18, 2005
Galapagos has announced that its services division BioFocus has reached agreement with the Swiss pharmaceutical company Serono to supply biologically-directed library compounds from its SoftFocus® collection throughout 2005-2006 for Serono's emerging drug discovery programs.
Furthermore, medicinal chemistry services already being provided by BioFocus will be expanded further to accelerate Serono's existing programs.
The combination of BioFocus' and Serono's capabilities have proven to be highly fruitful, and it is envisaged that this increased collaboration will lead to further drug discovery programs between the two companies.
Under the terms of the agreement, Galapagos will receive technology access fees for library compounds, plus a fee-for-service component for medicinal chemistry services.
“This expanded agreement with Serono fits very well within our strategy to provide integrated drug discovery services to pharma and biotech companies,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.
“We are pleased that our new division BioFocus has been able to secure this important deal for Galapagos.”
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE